Medicover Genetics Launches OncoSentia MRD Test for Unresectable NSCLC
The plasma-informed ctDNA test is for longitudinal MRD monitoring in unresectable stage II/III NSCLC and is offered through CAP/CLIA labs across European markets. Validation cites the DART study, which linked ctDNA to higher progression risk.